Who We Are
Onconox was founded to transform how medicine is developed, delivered, and experienced. By combining AI-driven discovery with advanced drug-device platforms, we reformulate validated molecules into smarter therapies that are safer, more effective, and faster to reach patients.
Our mission is clear:
To accelerate the delivery of innovative precision therapies that improve survival and quality of life in cancer, neurodegeneration, and respiratory disease.
Our vision:
To become the world’s leading platform biotech in repurposed drug-device therapeutics, transforming the way known molecules are used to solve medicine’s hardest problems.
We are powered by pioneers in drug delivery, translational science, and biotech entrepreneurship — supported by global partners and advisors — all united by one belief: every patient deserves therapies that are not just effective, but tolerable, targeted, and intelligently designed.
Who We Are
At Onconox, we are building a new model for how precision therapies are created, delivered, and brought to patients with high-burden diseases.
Our focus is to transform the potential of validated small molecules through targeted delivery technologies that maximize local therapeutic effect while minimizing systemic toxicity. By combining intelligent reformulation, advanced drug-device engineering, and AI-enabled discovery, we aim to solve some of medicine’s hardest problems in oncology and neurodegeneration.
We operate with a clear philosophy, capital discipline, and a platform architecture that scales. Our lead program OCN001, represents the first clinical proof point of this strategy, and the wider pipeline demonstrates how a single platform can generate multiple high-value assets with strong scientific, regulatory, and commercial foundations.
Our Vision & Mission
Our Vision
Our vision is to become the leading platform biotech redefining how proven molecules are deployed to tackle complex diseases. We seek to set a new standard for targeted drug-device therapeutics that offer high efficacy, low treatment burden, and meaningful improvements in survival and quality of life. Above all, we envision a future where precision-delivered therapies are accessible, scalable, and rapidly translated to patients who need them most.
Our Mission
Our mission is to accelerate the development of innovative, precision-targeted therapies for oncology and CNS disorders by applying advanced delivery technologies and AI-led discovery to validated pharmacology. We focus on capital-efficient execution, translational robustness, and strong regulatory alignment to bring first-in-class and best-in-class assets to the clinic faster, leaner, and with a clear path to impact.
Our Values
Patient-Centered Innovation
We engineer therapies that meaningfully improve the lives of people living with cancer and neurological diseases, with a focus on reducing toxicity, increasing tolerability, and supporting adherence.
Scientific Rigor & Precision
We combine validated pharmacology with cutting-edge delivery and AI-driven insight. Every program is designed with mechanistic clarity, strong translational foundations, and a commitment to clinical relevance.
Capital Discipline
We deploy capital deliberately, leveraging strategic partnerships, modular development processes, and efficient operating models that reduce risk while increasing the probability of clinical success.
Integrity & Accountability
We maintain a transparent, data-driven culture that guides decision-making, governance, and stakeholder engagement. Our commitments to patients, investors, partners, andregulators are anchored in operational excellence.
Scalable Platforms,
Not Single Assets
We build technologies that unlock multiple high-impact products. The BIG Platform exemplifies our philosophy: create repeatable, defensible innovation that outlives any single program.
Global Responsibility
We pursue therapies that are not only effective, but also accessible. Our approach is intentionally designed to unlock global potential, from high-income markets to regions where cost, toxicity, and treatment burden are critical barriers to care.
Onconox Leadership
Onconox is powered by a world-class leadership, board, and advisory team with decades of collective experience in oncology, drug development, translational science, and biotech commercialization. Together, they bring a proven track record in advancing novel therapies from discovery to clinical success, supported by deep expertise in scientific innovation, regulatory engagement, and strategic execution.
Our Team
Scientific Advisory Board
Boards of Directors
Our Culture
WHY WE DO WHAT WE DO
Onconox is built to be agile, capital-efficient, and impact-driven. We combine deep scientific expertise with disciplined execution, always guided by the principle that innovation must translate into meaningful outcomes for patients. We are committed to diversity, equity, and inclusion — ensuring our governance, team, and partnerships reflect the communities we aim to serve.